The neurosurgeon at Allegheny Health Network discussed the current uses of GammaTile following tumor removal, and the research needed to unlock greater potential. [WATCH TIME: 3 minutes]
Matthew Shepard, MD
Advertisement
Articles by Matthew Shepard, MD
Advertisement
Latest Updated Articles
FDA Approves Lecanemab Autoinjector, Marking First At-Home Treatment for Alzheimer DiseasePublished: August 29th 2025 | Updated: September 2nd 2025
Indirect Comparison Study Hints at Lower ARIA and ICH-Related Mortality Risk in Lecanemab Over DonanemabPublished: July 28th 2025 | Updated: July 30th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on TermPublished: May 14th 2025 | Updated: May 16th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack SeverityPublished: May 12th 2025 | Updated: May 13th 2025
- FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion CountsPublished: March 4th 2025 | Updated: March 19th 2025
Advertisement
Advertisement
Trending on NeurologyLive
1
Enhancing Gene Therapy Safety for Duchenne Through New Recommendations: Barry Byrne, MD, PhD
2
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
3
Expanding the Alzheimer Drug Development Pipeline
4
Patient-Reported Study Identifies Common Symptoms and Timing During Migraine Prodrome
5
